Business
Novo CEO Signals M&A Plans
Novo's new CEO, Mike Doustdar, is considering M&A opportunities to strengthen its drug pipeline amid growing competition in the weight-loss market.
Coverage timeline — 1 article
CNBC
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
2026-09-22 09:00 UTC